Voyageur Pharma enters distribution deal with Phalanx

Mr. Brent Willis reports VOYAGEUR PHARMACEUTICALS SIGNS NON-EXCLUSIVE DISTRIBUTION & WHOLESALE AGREEMENT WITH PHALANX Voyageur Pharmaceuticals Ltd. has signed a non-exclusive distribution agreement with Phalanx Comercializadora e Importadora de Componentes SA DE CV, a company based in Mexico. This agreement was established after the signing of a non-binding letter of intent announced on June 24, 2025. This agreement represents a mutual commitment between Voyageur and Phalanx to establish a strategic partnership and drive market expansion into the Mexican health care sector, specifically in the area of barium-based contrast media. Under this non-exclusive distribution and wholesaling framework, Phalanx will proceed with the registration of Voyageur's barium contrast media products with the appropriate Mexican health regulatory authorities and will distribute these products through Phalanx's established distribution network. Voyageur is fully committed to supporting Phalanx throughout this process, working collaboratively to advance regulatory approval, market access and commercialization efforts. This partnership marks a unifying step forward aligning both companies in a shared vision to establish and expand Voyageur's market presence within Mexico's medical imaging and contrast media markets. Phalanx is a leading pharmaceutical distributor with a strong presence in Mexico and key Latin American markets that recognize Canadian regulatory approvals. Phalanx provides comprehensive commercial intelligence and strategic market solutions for businesses entering the region. By combining rigorous market analysis with hands-on operational execution, Phalanx ensures successful product launches, optimized logistics and sustainable growth. Leveraging deep regulatory expertise, precise supply chain management and actionable market insights, Phalanx accelerates international expansion while minimizing risk and enabling global companies to establish a strong and compliant presence across Latin America. This partnership represents a key milestone in Voyageur's international growth strategy, further expanding the company's global footprint and supporting access to underserved markets with increasing demand for high-quality contrast media. "This agreement marks a significant step forward in our commercialization road map," said Brent Willis, chief executive officer of Voyageur. "It reflects our continued commitment to expanding global access to our innovative, cost-effective imaging solutions. Latin America is a critical market in our expansion plan, and this partnership lays the groundwork for long-term growth." Sales of Voyageur's barium sulphate contrast media products in Mexico and other Latin American countries will be subject to local regulatory approval processes. The distributor is expected to take the lead in preparing and submitting necessary filings with support from Voyageur's technical and regulatory team. About Voyageur Pharmaceuticals Ltd. Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium and iodine active pharmaceutical ingredients that offer high performance and cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast markets, Voyageur aims to become a key player by producing its own barium and iodine. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Voyageur's business plan is set to generate cash flow to prove economics for the Frances Creek barium contrast project feasibility study by working with established third party good manufacturing process pharmaceutical manufacturers in Canada thereby ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs. At the core of its operations, Voyageur owns a 100-per-cent interest in the Frances Creek project. Currently, the world's pharmaceutical barium sulphate is almost entirely synthetically produced resulting in a less effective imaging quality product. Voyageur's Frances Creek resource boasts a rare and exceptional-grade mineral suitable for the pharmaceutical marketplace that Voyageur believes will replace the current synthetic products with higher-quality imaging products. Voyageur's ambitious vision is to become the first vertically integrated company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to final production, Voyageur believes it can ensure quality and cost-efficiency. With its approach, it embodies the motto of from the earth to the bottle, highlighting Voyageur's commitment to responsible sourcing and manufacturing practices. We seek Safe Harbor.